Association between insulin resistance and prostate volume: A 4‐year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial
Patients with higher HOMA-IR had modestly larger PVs at baseline, year 2 and year 4, but insulin resistance was unrelated to PV change over four years. These findings suggest that insulin resistance may be a modifiable risk factor contributing to benign prostatic enlargement, though further research is needed to determine its clinical relevance.
Authors
- James P. Daniels (ORCID: https://orcid.org/0000-0002-2401-2474)
- Stephen J. Freedland (ORCID: https://orcid.org/0000-0002-8104-6419)
- James Mirocha (ORCID: https://orcid.org/0000-0002-2338-193X)
- Jordan Palmer
- Daniel Moreira (ORCID: https://orcid.org/0009-0002-8278-2570)
- Renning Zheng (ORCID: https://orcid.org/0009-0001-4286-2544)
- Alexander Hernández‐Tirado (ORCID: https://orcid.org/0000-0002-7757-7823)
Institutions
- Cedars-Sinai Medical Center (US)
- University of Louisville (US)
- Illinois College (US)
- University of Illinois Chicago (US)
- Durham VA Medical Center (US)
- A.T. Still University (US)
- Tsinghua University (CN)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/bco2.70085
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52